NCT00420511View on ClinicalTrials.gov

Beta-Cell Function and Sitagliptin Trial (BEST)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

sitagliptin 100 mg once a day

DRUG

Placebo

placebo once a day

DRUG

metformin

metformin 1000 mg twice a day (bid) by mouth (po)

Trial Locations (1)

M5T 3L9

Leadership Sinai Centre for Diabetes, Toronto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT00420511 - Beta-Cell Function and Sitagliptin Trial (BEST) | Biotech Hunter | Biotech Hunter